Needham analyst Ami Fadia maintained a Buy rating on Day One Biopharmaceuticals today and set a price target of $16.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ami Fadia has given his Buy rating due to a combination of factors tied to both Day One Biopharmaceuticals’ current commercial performance and its forward-looking prospects. She highlights that Ojemda’s full-year 2025 revenue meaningfully surpassed both her projections and market expectations, with fourth-quarter sales especially strong relative to prior estimates and company guidance. Management’s 2026 revenue outlook for Ojemda also exceeds consensus at the midpoint, suggesting continued robust demand and execution in the core franchise.
Fadia further underscores that the company’s pipeline adds to the upside potential, noting management’s plans to expand Ojemda outside the U.S. through partnership and advance the FIREFLY-2 Phase 3 trial in first-line pLGG toward a potential 2028 approval. She also points to upcoming clinical milestones, including mid-2026 Phase 1 data for Emi-Le and initial Phase 1a data for DAY301, which together could provide multiple value-creating catalysts. With 2026 positioned as a catalyst-heavy year ahead of the pivotal FIREFLY-2 readout in 2027, she sees a favorable risk-reward profile that supports her Buy recommendation on DAWN.
Fadia covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Day One Biopharmaceuticals, and Alkermes. According to TipRanks, Fadia has an average return of 23.3% and a 53.11% success rate on recommended stocks.
In another report released on January 6, Bank of America Securities also maintained a Buy rating on the stock with a $17.00 price target.